Trials / Completed
CompletedNCT01594268
A Prospective, Open Label Study of CERtican in KIdney Transplantation
A Prospective, Open-label Study to Assess Safety of Certican in Kidney Transplant Patients
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 54 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
A prospective, open label study of CERtican in KIdney transplantation
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Everolimus | A prospective, open-label study to assess safety of Certican in kidney transplant patients |
Timeline
- Start date
- 2012-03-01
- Primary completion
- 2013-10-01
- Completion
- 2013-10-01
- First posted
- 2012-05-09
- Last updated
- 2017-03-21
Locations
4 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT01594268. Inclusion in this directory is not an endorsement.